Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program

Boehringer IngelheimBoehringer Ingelheim, one of the world's leading pharmaceutical companies, recently announced to support two projects of its Making More Health Accelerator Program: Melissa Menke, CEO of Access Ayfa and Joost van Engen, CEO of Healthy Entrepreneurs.

Four social ventures participated in the 2018 - 2019 accelerator program, where they developed innovative business models to solve unmet medical needs in sub Saharan Africa. Boehringer Ingelheim will continue to support the scale up of two of these models through funding of €150,000 per social venture. By using this unique approach, Boehringer Ingelheim is creating a win for communities by developing innovative and sustainable care delivery models, thus improving access to healthcare.

Melissa Menke pitched for a comprehensive diabetes and hypertension screening and clinical management program within low-income populations. Her organization, Access Afya, is a primary healthcare enterprise providing quality healthcare to low income groups in slums in Nairobi, Melissa aims to have 50 clinics across Kenya by 2021. Joost Van Engen, the founder of Healthy Entrepreneurs, pitched on a last mile distribution model for medicines and other basic commodities in rural western Kenya through a network of community entrepreneurs. With this concept, Healthy Entrepreneurs will be able to offer screening services, disease awareness and provide, through a combination of telemedicine and in-person doctor visits, accessible and affordable healthcare services.

"The patients will be the most important part of this program. Many people do not have the right access to quality treatment in Africa. By supporting the social entrepreneurs, patients will be provided with better access to healthcare." Ayman Eissa, Head of Human Pharma, Boehringer Ingelheim META.

The Making More Health (MMH) Accelerator is an 11-month business accelerator program, designed through a collaboration between Boehringer Ingelheim and Ashoka. Boehringer's business insights combined with Ashoka's extensive knowledge on social entrepreneurship gives a perfect foundation to provide a structured process to engage with social entrepreneurs and co-create successful business models.

Boehringer Ingelheim's initiative "Making More Health" aims to establish a network of social enterprises in Kenya, Nigeria and Ghana by building an ecosystem ‘on the ground’ which will help in developing holistic models that will sustainably provide quality healthcare to underserved communities.

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...